Efficacy and Safety of Camrelizumab in Real-World Prospective Study
1 other identifier
observational
1,000
0 countries
N/A
Brief Summary
This observational real-world study is designed to evaluate the efficacy and safety of camrelizumab for the treatment of Chinese NSCLC patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2021
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 8, 2021
CompletedFirst Posted
Study publicly available on registry
March 11, 2021
CompletedStudy Start
First participant enrolled
April 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 30, 2024
CompletedMarch 11, 2021
March 1, 2021
3.2 years
March 8, 2021
March 8, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
AE,Grade 3-5
Safety of the general population:Serious Adverse Events (AE)，Grade 3-5.
From April 1, 2021 to Septeember 30, 2024
Secondary Outcomes (6)
pCR
From April 1, 2021 to December 30, 2024
MPR
From April 1, 2021 to December 30, 2024
R0 resection rate
From April 1, 2021 to December 30, 2022
ORR
From April 1, 2021 to December 30, 2022
PFS
From April 1, 2021 to December 30, 2022
- +1 more secondary outcomes
Interventions
Camrelizumab-treated advanced NSCLC Patients with advanced non-small cell lung cancer treated with camrelizumab. Dosage form, dosage, frequency and duration of camrelizumab is determined according to the investigator's actual clinical practice.
Eligibility Criteria
Total 1000 patients who should accept camrelizumab with NSCLC will be enrolled. The patients should be registered consecutively in each site.
You may qualify if:
- Sign the informed consent and volunteer to participate in the study;
- Non-small cell lung cancer confirmed by histological/cytopathological tests;
- Age ≥18;
- The investigators determined that patients should receive camrelizumab alone or in combination.
You may not qualify if:
- Patients who are also receiving other immunomedications or therapies;
- Patients participating in other interventional studies;
- Patients complicated with other malignant tumors;
- Women who have been confirmed to be pregnant or lactating;
- The Investigator considers the patient unsuitable for participation in any other condition of the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Yilong Wu
Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 8, 2021
First Posted
March 11, 2021
Study Start
April 1, 2021
Primary Completion
June 30, 2024
Study Completion
December 30, 2024
Last Updated
March 11, 2021
Record last verified: 2021-03